A prospective comparative study of intravesical bacillus Calmette-Guérin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer.

[1]  U. Studer,et al.  Abstract 2691: A randomized Phase III study comparing the efficacy of Bacillus Calmette Guérin strain Tice versus Connaught for immunotherapy of non-muscle invasive bladder cancer , 2012 .

[2]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. , 2011, European urology.

[3]  H. Herr,et al.  History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. , 2008, The Journal of urology.

[4]  R. Sylvester,et al.  Prognostic Factors in Non–Muscle-Invasive Bladder Tumors: I. Clinical Prognostic Factors: A Review of the Experience of the EORTC Genito-Urinary Group II. Biologic Prognostic Markers , 2007 .

[5]  P. Malmström,et al.  Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin‐C and bacillus Calmette‐Guérin in patients with high‐risk bladder cancer , 2007, BJU international.

[6]  D. Margel,et al.  Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy. , 2007, Urology.

[7]  I. Yano,et al.  Bacillus calmette-guerin Tokyo172 substrain for superficial bladder cancer: characterization and antitumor effect. , 2005, The Journal of urology.

[8]  H. Akaza,et al.  A clinical study of PMCJ-9 (Bacillus Calmette-Guérin Connaught strain) treatment of superficial bladder cancer and carcinoma in situ of the bladder. , 2003, Japanese journal of clinical oncology.

[9]  D. Lamm,et al.  Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. , 2002, The Journal of urology.

[10]  J. Patard,et al.  Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer. , 2001, Urology.

[11]  D. Lamm,et al.  Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. , 2000, The Journal of urology.

[12]  M. Behr,et al.  A historical and molecular phylogeny of BCG strains. , 1999, Vaccine.

[13]  K. Tozawa,et al.  Clinicopathological evaluation of repeated courses of intravesical bacillus Calmette-Guerin instillation for preventing recurrence of initially resistant superficial bladder cancer. , 1996, The Journal of urology.

[14]  C. Leclerc,et al.  Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains , 1996, Infection and immunity.

[15]  H. Akaza,et al.  Bacillus calmette—Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four‐year results , 1995 .

[16]  Michael Cookson,et al.  Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. , 1992, The Journal of urology.

[17]  D. Lamm,et al.  Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. , 1989, The Journal of urology.